| Drug Name |
Carbidopa |
| Drug ID |
BADD_D00359 |
| Description |
Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394]
The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113] |
| Indications and Usage |
For treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism |
| Marketing Status |
Prescription |
| ATC Code |
Not Available |
| DrugBank ID |
DB00190
|
| KEGG ID |
D00558
|
| MeSH ID |
D002230
|
| PubChem ID |
34359
|
| TTD Drug ID |
D0P7JZ
|
| NDC Product Code |
67628-2001; 43386-980; 70771-1355; 63415-0024; 38779-0202; 51407-314; 42799-123; 65977-0131; 70600-018; 12780-4420; 52423-0901; 0006-0007; 62331-014; 62991-2848; 25010-711; 16714-067; 63629-1932; 43975-220; 59651-146; 58624-0621; 49452-1692; 70710-1221; 40032-980; 51504-0001 |
| Synonyms |
Carbidopa | Methyldopahydrazine | MK-486 | MK 486 | MK486 | Lodosin | Lodosyn | MK-485 | MK 485 | MK485 | Carbidopa, (S)-Isomer | Carbidopa, (R)-Isomer |
